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Abstract 
Erythropoietin (EPO) directly stimulates the proliferation of vascular smooth 
muscle cells, and this is believed to be one of the mechanisms of vascular 
access failure of hemodialysis patients. However, precise mechanisms of the 
EPO-induced proliferation of vascular smooth muscle cells are not certain. 
HMG-CoA reductase inhibitors (statins) are primarily used to reduce cholesterol 
levels, but also exert other effects, including reno-protective effects. We 
evaluated the effect of several statins with various hydrophilicities on the 
EPO-induced proliferation of primary cultured rat vascular smooth muscle cells 
(VSMCs) in vitro. EPO significantly and concentration-dependently increased 
DNA synthesis as assessed by [3H]thymidine incorporation, cell proliferation as 
assessed by WST-1 assay, and activation of the p44/42MAPK pathway. 
Therapeutic doses of statins (pravastatin, simvastatin, atorvastatin and 
fluvastatin) in patients with hypercholesterolemia almost completely suppressed 
all of the EPO-induced effects in a concentration-dependent manner. 
Co-addition of mevalonic acid almost completely reversed the effects of statins. 
Statin alone did not affect the basal proliferation capacity of the cells. The effects 
were almost similar among the statins. We concluded that statins inhibited 
EPO-induced proliferation in rat VSMCs at least partly through their inhibition of 
HMG-CoA reductase activity. In the future, statins might prove useful for the 
treatment of EPO-induced hyperplasia of vascular access. Because the statins 
all showed comparable effects irrespective of their hydrophilicities, these effects 
might be a class effect.  
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1. Introduction 
Erythropoietin (EPO) is the main glycoprotein growth factor that regulates the 
survival, proliferation, and differentiation of erythroid progenitor cells.(Krantz, 
1991) Its receptor is expressed not only in these cells but also in vascular 
smooth muscle cells (VSMCs) and endothelial cells.(Ammarguellat et al., 1996) 
as well as neuronal and glial cells (Ntaigos et al, 2008). EPO is important for the 
treatment of renal anemia, and correction of anemia by the drug improves the 
quality of life in patients with renal failure. However, EPO can contribute to 
stenosis and occlusion of vascular access for hemodialysis by promoting 
hyperplasia of vascular wall and thrombosis (Himmelfarb et al., 2005; Lee et al., 
2009). Some studies in vivo have shown that long term EPO therapy may not 
increase the risk of stenosis of the arteriovenous fistula. (De Marchi et al.,1997) 
Vascular access failure is a major cause of morbidity and hospitalization in 
hemodialysis populations worldwide (Himmelfarb et al., 2005; Roy-Chaudhury et 
al., 2006). However, no pharmacological approach to avoid the EPO-related 
adverse reaction were developed until present time. EPO also causes 
hypertension in 20-30% of hemodialysis patients(Maschio, 1995) and the 
EPO-induced hyperplasia of blood vessel is believed as one of the mechanisms 
of the hypertension (Eggena et al., 1991; Hand et al., 1995).  
The mechanism of EPO-induced hyperplasia of vascular wall is not fully 
understood. Intravenous administration of EPO results in a severe, but transient, 
increase in drug concentration within the vascular access. It has been reported 
that EPO acts directly on VSMCs in vitro, such as by  increasing their 
cytoplasmic Ca++ concentration, causing contraction(Akimoto et al., 2001) and 
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stimulating proliferation(Ito et al., 2002). In erythroid cells, EPO stimulates 
several signal transduction systems for cell proliferation, such as JAK-STAT, 
RAS-MAPkinase, inositol phosphate, and PI3K-AKT. Among these systems, the 
MAP kinase cascade is the most important for the cell proliferation stimulated by 
EPO.(Nishida and Gotoh, 1993)  EPO also stimulates vasoconstriction by 
activation of the local renin angiotensin system,(Eggena et al., 1991) increased 
vasoconstrictor response to catecholamines,(Hand et al., 1995) and effects on 
prostaglandins(Bode-Böger et al., 1996), and actions on the endothelium, such 
as increased endothelin production(Nagai et al., 1995) and modification of 
endothelial function.(Ioka et al., 2009) 
 
HMG-CoA reductase inhibitors (statins) are used for the treatment of 
hypercholesteremia, which they ameliorate in part by decreasing the generation 
of mevalonic acid from acetate in the liver.(Yusuf et al., 2009) The most 
important adverse reaction of these drugs is rhabdomyolysis although it is rare 
except in patients also receiving some agents such as cyclosporine, nicotinic 
acid, and gemfibrozil.(Yusuf et al., 2009) Statins are partly excreted into 
urine.(Lennernäs and Fager, 1997) Therefore, the prescription of statins to 
patients with renal failure patients needs to be handled with caution. On the 
other hand, statins possess pleiotropic effects,  such as the improvement of 
endothelial function, anti-inflammatory effects, anti-oxidant effects and inhibition 
of cell proliferation.(Liao and Laufs, 2005) It has also been reported that statins 
protect against renal injury in both clinical and basic researches.(Navaneethan 
et al., 2009a; Navaneethan et al., 2009b) There are a number of negative 
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controlled trials, which have demonstrated that statins are ineffective in 
preventing cardiovascular disease in hemodialysis patients. (Fellström BC et al., 
2009) However, their pleiotropic effects on other sites (such as VSMCs) may still 
be of benefit to the patient.  
 
The purpose of this study was to evaluate the effect of statins on EPO-induced 
cell proliferation in rat VSMCs in vitro. Because the hydrophilicities of statins 
vary,(Lennernäs and Fager, 1997) we used several hydrophilic and lipophilic 
statins and compared their effects. We also assessed the pathway through 
which statins exhibit their effect using mevalonic acid. 
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2. MATERIALS AND METHODS 
2.1 Materials 
All materials were obtained from Sigma Chemical Co. (St. Louis, MO) except for 
the following. Recombinant human erythropoietin (epoetin-alfa, EPO) was a 
generous gift from Chugai Pharmacological (Tokyo, Japan). Pravastatin and 
fluvastatin were supplied from Daiichi-Sankyo Company Limited (Tokyo, Japan). 
Simvastatin was purchased from Wako Chemical (Osaka, Japan). The p44/42 
MAPK assay kit and the anti-p44/42 MAPK and anti-phospho-p44/42 MAPK 
(Thr202/Try204) antibodies were purchased from Cell Signaling Technology 
(Beverly, MA, USA). [3H]Thymidine was purchased from Perkin Elmer Life 
Sciences (Boston, MA, USA). Pravastatin and fluvastatin were dissolved with 
deionized water, while atorvastatin and simvastatin were dissolved with DMSO 
(0.005% at final concentration) and ethanol (0.005% at final concentration), 
respectively. 
 
2.2 Cell culture 
Primary culture of VSMCs were isolated from the aortas of male 
Sprague–Dawley rats (150–200 g; purchased from Japan SLC, Inc., Shizuoka, 
Japan) as previously described.(Ito et al., 2002),(Yamamoto et al., 
2006),(Akimoto et al., 2001) In brief, primary culture of VSMCs were identified by 
their typical hill and valley morphology and by indirect immunofluorescent 
staining for a-smooth muscle actin (R&D Systems Inc., Minneapolis, MN, USA). 
The VSMCs were maintained in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) (ICN Biomedicals, Osaka, 
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Japan), 100 U/ml penicillin, and 100 mg/ml streptomycin (Life Technology Inc., 
Rockville, MD, USA) in a 5% CO2 incubator at 37°C. The cells were used 
between passages 3 and 8. Mono-layered VSMCs at 70–80% confluence were 
growth-arrested by incubation in DMEM with 0.5% FBS for 48 h and served for 
the experiments. We measured endotoxin concentration in the medium by the 
limulus amebocyte lysate method (Wako Pure Chemical Industries, Osaka, 
Japan) and found that it was under the detection limit, which strongly indicated 
the absence of lipopolysaccharide in the medium.  All procedures were 
conducted in accordance with the Jichi Medical School guide for laboratory 
animals. 
 
2.3 [3H]Thymidine incorporation(Yamamoto et al., 2006) 
The cells were seeded on 24-well culture plates, allowed to grow to 70–80% 
confluence, and then growth-arrested by incubation in DMEM with 0.5% FBS for 
48 h. The cells were incubated for 24 h with EPO (or 10% FBS as a positive 
control), and [3H]thymidine (1 mCi/ml; specific activity, 79 Ci/mmol) was added 
for the last 6 h of the incubation period. The cells were then washed three times 
with phosphate-buffered saline, treated with ice-cold 10% trichloroacetic acid at 
4°C for 15 min, and washed with phosphate-buffered saline. The acid-insoluble 
material was dissolved in 0.5 ml of 0.3 N NaOH. The protein content was 
measured by a DC Protein Assay (Bio-Rad, Hercules, CA, USA), and 
radioactivity was determined by using a liquid scintillation counter (Aloka, Tokyo, 
Japan). 
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2.4 WST-1 assay for Cell proliferation(Yamamoto et al., 2006) 
VSMC proliferation was assessed using a Cell Counting Kit.(Yamamoto et al., 
2006) The cells were seeded at a density of 5×103 cells/well on 96-well culture 
plates in DMEM with 10% FBS for 72 h. After serum starvation for 48 h in DMEM 
with 0.5% FBS, the cells were stimulated by EPO (or 10% FBS as a positive 
control) for 24 h. For the final 4 h of incubation, 
4-[3-[4-lodophenyl]-2-4(4-nitrophenyl)-2H-5-tetrazolio-1,3-benzene disulfonate] 
was added to each well and the absorbance was measured at 450 nm with a 
reference wavelength of 650 nm using a microplate spectrophotometer system 
(SOFTmax PRO; Molecular Devices Corporation, Sunnyvale, CA, USA). The 
difference of absorbance between 450 and 650 nm was regarded as the cell 
proliferation. 
 
2.5 Western blot analysis (Yamamoto et al., 2006) 
Growth-arrested cells cultured in 100-mm dishes were stimulated by EPO or 
10% FBS as a positive control for the indicated times. The cells were washed 
with ice-cold phosphate-buffered saline and lysed in 400 l of lysis buffer (1% 
Triton, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM 
ethyleneglycol tetraacetate, 2.5 mM sodium pyrophosphate, 1 mM 
-glycerophosphate, 1 mM Na3VO4, 1 mg/ml L-leupeptin, 1 mM 
phenylmethylsulfonyl fluoride) for 30 min at 4°C. The cell lysates were 
centrifuged for 15 min at 15,000 g and the supernatants were collected. Equal 
amounts of protein (20 g) were separated by 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis, and electrophoretically transferred to 
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polyvinylidine difluoride membranes (Invitrogen Corp., Carlsbad, CA, USA). The 
membranes were blocked for 1 h at room temperature with Tris-buffered saline 
containing 0.05% Tween 20 (TBS-T) and 5% bovine serum albumin. After 
washing with TBS-T, the membranes were incubated overnight with 
phospho-p44/42 MAPK (Thr202/Tyr204) antibody (1:1000) or p44/42 MAPK 
antibody (1:1000) at 4°C with gentle shaking. The primary antibodies were 
detected using horseradish peroxidase-conjugated goat antirabbit IgG and 
visualized by enhanced chemiluminescence Western blotting reagents 
(Amersham Biosciences, Buckinghamshire, UK). Band intensity was analyzed 
using a lumino-image analyzer (LAS-3000 min; Fuji Film Company Limited, 
Tokyo, Japan). 
 
2.6 Statistics 
The results are expressed as the mean± S.E.M. Number of each experiment 
was 3 to 6. Data were analyzed by the unpaired Student's t-test or by one-way 
analysis of variance combined with Fisher's protected least significant difference 
using a personal computer with StatView version 5.0 software (SAS Institute, 
Cary, NC, USA). Values of P<0.05 were considered to indicate statistical 
significance. Figures are each representative of three or more experiments. 
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3. Results 
3.1 EPO increased [3H]thymidine incorporation and cell proliferation, and 
activated the p44/42MAPK pathway in rat VSMCs 
 
First, we tried to confirm the previous finding about EPO-stimulated 
[3H]thymidine incorporation and cell proliferation. As shown in Fig.1, EPO 
increased [3H]thymidine incorporation in a concentration-dependent manner. 
The increase was significant at concentrations of 120 IU/ml or higher, and thus 
120 IU/ml EPO was the concentration used in the following experiments. 10% 
FBS, which was used as a positive control, also increased the thymidine 
incorporation. VSMC proliferation determined by WST-1 assay was also 
increased by addition of EPO in a concentration-dependent manner, and the 
increase was significant at 120 IU/ml or more (Fig.2).  
To identify further intracellular signaling events involved in the effects of EPO on 
the rat VSMC proliferation, we investigated the activation of p44/42 MAPK in 
VSMCs. We confirmed in a preliminary study that the phosphorylation of p44/42 
MAPK was most prominent when EPO was added for 5 min (data not shown). As 
shown in Fig.3, EPO activated the p44/42MAPK pathway in a 
concentration-dependent manner, and the activation was significant at more 
than 30 IU/ml. Thus we confirmed the previous finding (Ito et al., 2002) that EPO 
increases [3H]thymidine incorporation and cell proliferation, and activates the 
p44/42MAPK pathway in rat VSMCs. According to these findings, we selected 
120 IU/ml of EPO for the following experiments to determine the effect of statins 
on EPO-induced VSMC proliferation. 
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3.2 EPO-stimulated VSMC proliferation was prevented by pravastatin via 
inhibition of HMG-CoA reductase activity 
 
As shown in Fig.4, pravastatin significantly inhibited EPO-stimulated 
[3H]thymidine incorporation. The inhibition was partial at 10 nM and was 
complete at more than 100 nM, and the latter concentration is compatible with 
the plasma maximum concentration in clinical use. Furthermore, 100 nM 
pravastatin alone did not affect the [3H]thymidine incorporation. These results 
indicated that the therapeutic dose of pravastatin did not affect basal DNA 
synthesis, but inhibited EPO-stimulated DNA synthesis in rat VSMCs.  
In order to evaluate whether the effect of pravastatin was due to inhibition of 
HMG-CoA reductase by the drug, we added mevalonic acid with pravastatin. As 
shown in Fig.5A, co-addition of mevalonic acid (100 µM) partly recovered the 
pravastatin-inhibited [3H]thymidine incorporation stimulation. This result 
indicated that EPO-stimulated DNA synthesis was prevented by inhibition of 
HMG-CoA reductase by pravastatin. 
A similar inhibitory effect of pravastatin via suppression of HMG-CoA reductase 
activity was observed in EPO-induced cell proliferation and activation of MAPK. 
As shown in Fig.5B, EPO-induced cell proliferation was inhibited by pravastatin, 
and this effect was reversed by co-addition of mevalonic acid. Figure 5C shows 
that phosphorylation of MAPK was activated by EPO and it was inhibited by 
addition of pravastatin. Furthermore, the inhibition by pravastatin was reversed 
by co-addition of mevalonic acid. Thus pravastatin suppressed VSMC 
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proliferation via the inhibition of HMG-CoA reductase activity. 
 
3.3 Effects of simvastatin, atorvastatin, and fluvastatin on EPO-induced VSMC 
proliferation 
 
Next, we evaluated the effects of other statins. Similar to pravastatin, , 
simvastatin  (up to 1000 nM)  inhibited EPO-induced [3H]thymidine 
incorporation in a concentration-dependent manner, and the inhibition was 
significant when the dose was more than 100 nM, while simvastatin at 100 nM 
alone did not affect the [3H]thymidine incorporation (data not shown). As shown in 
Fig. 6A, the inhibition by 100 nM of simvastatin was reversed by co-addition of 
mevalonic acid (100 µM). The stimulation of cell proliferation by EPO was also 
decreased by simvastatin and also reversed by co-addition of mevalonic acid (Fig. 
6B). Activation of p44/42MAPK by EPO was inhibited by simvastatin and also 
reversed by co-addition of mevalonic acid (Fig. 6C). 
We also evaluated atorvastain and fluvastatin. These two statins (up to 1000 
nM) also inhibited EPO-induced [3H]thymidine incorporation in a 
concentration-dependent manner, and the inhibition was significant when the 
dose was more than 100 nM, while statins at 100 nM alone did not affect the 
[3H]thymidine incorporation (data not shown). The inhibition of [3H]thymidine 
incorporation by 100 nM of the drugs was reversed by co-addition of mevalonic 
acid (100 µM). The EPO-stimulated cell proliferation was also decreased by 
statins and also reversed by co-addition of mevalonic acid. Activation of 
p44/42MAPK by EPO was inhibited by the statins and also reversed by 
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co-addition of mevalonic acid (Table 1 and 2). 
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4. Discussion 
Before we evaluated the effects of EPO on statins, we first tried to confirm the 
previous findings that EPO stimulated VSMC proliferation in vitro.(Ito et al., 
2002) We found that EPO at a concentration of more than 120 IU/ml stimulated 
thymidine uptake and DNA synthesis, and subsequently increased cell 
proliferation. The concentration needed for the stimulation was also compatible 
with previous reports. We also found that EPO activates phosphorylation of 
MAPK. This is compatible with previous results that EPO activated Raf-1 and 
MEK, which are upstream of the MAPK cascade in VSMC.(Carroll et al., 1991; 
Ito et al., 2002) 
After this confirmation, we demonstrated that statins inhibited the EPO-induced 
proliferation of VSMCs, which was the most important observation in this study. 
In addition to their effects on cell proliferation, we also found that statins 
prevented DNA synthesis and activation of MAPK by EPO. It has previously 
been reported that statins inhibited the VSMC proliferation induced by several 
growth-factors.(Rupérez et al., 2007; Sakamoto et al., 2005) However, an 
inhibitory effect of statins on EPO-induced proliferation has not been reported. 
EPO-induced hypertension is one of the most important adverse reactions of the 
drug(Maschio, 1995). EPO-induced VSMC proliferation in vitro has been 
reported as a possible model for use in investigating the mechanisms of 
EPO-induced hypertension. Therefore, our present finding that statins inhibited 
EPO-stimulated VSMC proliferation suggests a possible future application of 
statins for reversing EPO-induced hypertension in patients with renal anemia. 
It has been reported that statins inhibit the growth factor-induced proliferation of 
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several types of cells, including VSMCs.(Rupérez et al., 2007; Sakamoto et al., 
2005) But the doses used in these studies were on the micromolar order, which 
is larger than the therapeutic doses used for the treatment of 
hyperlipidemia.(Rupérez et al., 2007; Sakamoto et al., 2005) It has also been 
reported that the basal VSMC proliferation capacity without stimulants was 
inhibited by a pharmacological dose of statins.(Bellosta et al., 2004) In our study, 
the dose of statins required to inhibit the cell proliferations was about 100 nM, 
which is lower than those reported in the literature and close to the therapeutic 
dose required for the treatment of hyperlipidemia.(Lennernäs and Fager, 1997) 
Furthermore, the administration of 100 nM of statin alone did not affect the basal 
VSMC proliferation in this study. Thus, our findings indicated that lower or 
therapeutic doses of statins did not inhibit basal VSMC proliferation but 
prevented the EPO-stimulated proliferation.. 
Because statins primarily inhibit HMG-CoA reductase activity and generation of 
mevalonic acid from HMG-CoA in the liver,(Yusuf et al., 2009) we evaluated the 
effect of co-addition of mevalonic acid with statins in order to examine the  
mechanism of the preventive effect of statins on the EPO-induced cell 
proliferation. We found that co-addition of mevalonic acid with statins partly 
reversed the effect of statins. This result indicated that the effect of statins 
observed in this study was at least partly related to the inhibition of HMG-CoA 
reductase by the drug. It is uncertain how inhibition of HMG-CoA reductase 
activity leads to inhibition of VSMC. It has also been reported that statins have 
several pleiotropic effects that are not related to their inhibition of HMG-CoA 
reductase,(Liao and Laufs, 2005) and such effects may also have played a role 
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in the present findings. 
We evaluated four statins in this study. Although all these drugs equally inhibit 
HMG-CoA reductase, their hydrophilicities vary.  Pravastatin is the most 
hydrophilic and simvastatin is the most lipophilic among commercially available 
statins, while atorvastatin and fluvastatin are intermediate.(Yusuf et al., 2009) 
The prevention of EPO-induced VSMC proliferation by the statins obtained in 
this study was not dependent on the hydrophilicity of the drug, and seems to be 
a class effect. On the other hand, it has also been reported that lipophilic statins 
inhibit cell proliferation induced by serum, while pravastatin, a hydrophilic statin, 
does not inhibit the cell proliferation in SV40-transfected smooth muscle cells in 
mice.(Sindermann et al., 2000) The authors of this previous study speculated 
that pravastatin is hydrophilic and less permeable to the cell membrane if 
specific transporters of the drug are not present, while other lipophilic statins can 
enter into the cell without the assistance of transporters. Pravastatin is a 
substrate of organic anion transporting polypeptide (OATP), and OATP is 
expressed in some muscle cells.(Ieiri et al., 2009) Therefore, although all statins 
inhibited EPO-induced VSMC proliferation in the present study, the mechanism 
by which the different statins entered into the VSMCs may have differed. It is 
also reported that some lipophilic statins induced apoptosis of VSMCs (Katsiki N, 
et al., 2009), which may affect to the phenomenon observed in this study. 
In this study, we confirmed the previous finding that EPO stimulated VSMC 
proliferation, and the dose of EPO required for this stimulation was comparable 
with those reported previously.(Akimoto et al., 2001),(Ammarguellat et al., 1996; 
Ito et al., 2002) In a clinical setting, the plasma concentration of EPO after 
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repeated dosing is reported to be about 10 times lower than the dose used in 
this study.(Krzyzanski et al., 2005) However, Intravenous administration of EPO 
which is often used in hemodialysis patients, results in a severe, but transient, 
increase in drug concentration within the vascular access. Therefore, 
concentration of EPO used in this vitro study is enough to consider the 
mechanism of EPO-induced vascular access failure in hemodialysis patients. 
We used rat VSMC in this study, which is a limitation of this study to consider 
mechanism of EPO-induced vascular access failure in hemodialyis patients. 
Future study is needed to solve the problem. 
 
In conclusion, statins inhibited EPO-induced DNA synthesis, cell proliferation 
and activation of MAPK. The effect was comparable with all statins irrespective 
of their hydrophilicity, and thus may be a class effect. Although the treatment of 
renal failure patients with statins should be handled with caution, these drugs 
have been reported to have beneficial effects for the treatment of renal disease, 
and thus the opportunities to use statins for the treatment of renal failure patients 
will likely continue to increase. Our findings may be useful for the treatment of 
EPO-induced vascular access failure in renal failure patients.   
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Table 1. Effect of atorvastatin (ATV) and mevalonic acid (MVA) on 
EPO-induced VSMC proliferation. 
 
Concentrations of EPO, ATV and MVA were 120 IU/ml, 100nM and 100mM, 
respectively. 
Values are the mean ± S.E.M aP<0.05 compared with vehicle. bP<0.05 
compared with EPO alone. cP<0.05 compared with EPO＋ATV. NA: not 
available. n=3 to 6. 
Table 2. Effect of fluvastatin (FLV) and mevalonic acid (MVA) on 
EPO-induced VSMC proliferation. 
 
Concentrations of EPO, FLV and MVA were 120 IU/ml, 100nM and 100mM, 
respectively. 
Values are the mean ± S.E.M. aP<0.05, bP<0.01 compared with vehicle. cP<0.05 
compared with EPO alone. dP<0.05 compared with EPO＋FLV. NA; not available. 
n=3 to 6. 
 
 [3H]thymidine 
incorporation (fold 
increase) 
Cell proliferation 
(fold increase) 
phosphorylated 
p44/42 MAPK 
(fold increase) 
vehicle 1.00 ± 0.02 1.00 ± 0.03 1.0± 0.4 
EPO 1.21 ± 0.03a 1.18 ± 0.06a 5.2 ± 1.2a 
EPO+ATV 0.98 ± 0.04b 1.03 ± 0.03b 1.1 ± 0.3b 
EPO+ATV+MVA 1.11 ± 0.06c 1.15 ± 0.05c 3.2± 0.9c 
ATV 1.02 ± 0.03 0.99 ± 0.06 0.9 ± 0.3 
10% FBS 1.33 ± 0.10a 1.34 ± 0.09a NA 
 [3H]thymidine 
incorporation (fold 
increase) 
Cell proliferation 
(fold increase) 
phosphorylated 
p44/42 MAPK 
(fold increase) 
vehicle 0.99 ± 0.04 1.00 ± 0.02 1.0± 0.6 
EPO 1.29 ± 0.03a 1.24 ± 0.07 a 3.3 ± 1.4 a 
EPO+FLV 0.89 ± 0.08 c 0.99 ± 0.01 c 1.4 ± 0.3 c 
EPO+FLV+MVA 1.02 ± 0.03d 1.17 ± 0.05d 4.1± 1.2d 
FLV 0.97 ± 0.03 1.04 ± 0.03 1.8 ± 0.8 
10% FBS 5.04 ± 0.11 b 2.58 ± 0.13 b NA 
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Figure legends 
Fig. 1 Effect of EPO on the proliferation of VSMCs as assessed by DNA 
synthesis. 
Growth-arrested VSMCs were stimulated by EPO and FBS for 24 h. 
[3H]Thymidine was added for the last 4 h. 10% FBS was used as a positive 
control. Values are the mean ± S.E.M.(n=3). *P<0.05 compared with vehicle 
(10% PBS). 
 
Fig. 2 Effect of EPO on the proliferation of VSMCs as assessed by WST-1 
Growth-arrested VSMCs were stimulated by EPO and FBS for 24 h. WST-1 
was added for last 4 h. 10% FBS was used as a positive control. Absorbance 
was measured by using a microplate spectrophotometer. Values are the mean ± 
S.E.M.(n=6). *P<0.05,**P<0.01 compared with the vehicle. 
 
Fig. 3 Effect of EPO on p44/42MAPK phosphorylation. 
Growth-arrested VSMCs were stimulated by EPO for 5 min. (a) 
Representative immunoblots are shown with antibodies that recognize 
phosphorylated p44/42 MAPK and total p44/42 MAPK. (b) Densitometric 
analysis of phosphorylated p44/42 MAPK. Values are the mean ± S.E.M. 
(n=4).*P<0.05 compared with the vehicle. 
 
Fig. 4 Effect of pravastatin (PRV) on the EPO-induced increase of DNA 
synthesis in VSMCs. 
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Growth-arrested VSMCs were stimulated by EPO, PRV and FBS for 24 h. 
Values are the mean ± S.E.M. (n=3-6). *P<0.05, **P<0.01 compared with vehicle. 
#P<0.05 compared with EPO 120 IU/ml without pravastatin.  
 
Fig. 5  Effect of pravastatin (PRV) and mevalonic acid on EPO-induced 
VSMC proliferation. 
(A) DNA synthesis was evaluated by measuring [3H]thymidine uptake. 
Values are the mean ± S.E.M.（n=3). *P<0.05, **P<0.01 compared with vehicle. 
#P<0.05 compared with EPO 120 IU/ml. $P<0.05 compared with EPO 120 IU/ml
＋PRV 100 nM.  
(B) Cell proliferation was measured by WST-1 proliferation assay. Values are 
the mean ± S.E.M. (n=6). *P<0.05 compared with vehicle. #P<0.05 compared 
with EPO 120 IU/ml. $P<0.05 compared with EPO 120 IU/ml＋PRV 100 nM.  
(C) Representative immunoblots and densitometric analysis of p44/42 
MAPK and phosphorylated p44/42 MAPK. Values are the mean ± S.E.M.（n＝3). 
*P<0.05 compared with vehicle. #P<0.05 compared with EPO 120 IU/ml. 
$P<0.05 compared with EPO 120 IU/ml＋PRV 100 nM. 
 
  
 
Fig. 6  Effect of simvastatin (SMV) and mevalonic acid on EPO-induced 
VSMC proliferation. 
(A) DNA synthesis were evaluated by measuring [3H]thymidine uptake. 
Values are the mean ± S.E.M.(n=3). **P<0.01 compared with vehicle. ##P<0.01 
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compared with EPO 120 IU/ml. $$P<0.01 compared with EPO 120 IU/ml + 
SMV100 nM. 
(B) Cell proliferation was measured by WST-1 proliferation assay. Values are 
the mean ± S.E.M. (n=6). *P<0.05, **P<0.01 compared with vehicle. #P<0.05 
compared with EPO 120 IU/ml. $P<0.05 compared with EPO 120 IU/ml + 
SMV100 nM. 
(C) Representative immunoblots and densitometric analysis of p44/42MAPK 
and phosphorylated p44/42 MAPK. Values are the mean ± S.E.M.(n＝3). 
**P<0.01 compared with vehicle. ##P<0.01 compared with EPO 120 IU/ml. 
$$P<0.01 compared with EPO 120 IU/ml + SMV100 nM. 
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